Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline

7 March 2022
Contact
WHO Health Emergencies - Infection Prevention and Control
Avenue Appia 20, 1211 Geneva 27, Switzerland
WHEIPC@who.int

Disclaimer
COVID-19 infection prevention and control: Living guideline, 7 March 2022
© World Health Organization 2022. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.
WHO reference number: WHO/2019-nCoV/ipc/guideline/2022.1
Sections

Executive Summary ................................................................................................................................................. 4
Definitions ............................................................................................................................................................... 5
Abbreviations ......................................................................................................................................................... 5

Methodology ............................................................................................................................................................ 7

Part 1: Health care settings (coming soon) .............................................................................................................. 10

What is an IPC program? (coming soon) .................................................................................................................. 11
Environmental cleaning .......................................................................................................................................... 11
Home care for patients .......................................................................................................................................... 11
IPC when COVID-19 is suspected or confirmed .................................................................................................... 11
IPC principles and procedures for COVID-19 vaccination activities .................................................................... 11
Long term care facilities ........................................................................................................................................ 11
Mask use ................................................................................................................................................................. 11
PPE Technical Specifications .................................................................................................................................. 12
Prevention, identification and management of health worker infection ................................................................... 12
Rational use of PPE and considerations during severe shortages ......................................................................... 12
Risk assessment and management of exposure ...................................................................................................... 12
Safe dead body management ................................................................................................................................ 12
Water, sanitation, hygiene, and waste management .............................................................................................. 12

Part 2: Community settings ................................................................................................................................... 13

Introduction to public health and social measures ................................................................................................. 13
Safe dead body management ................................................................................................................................ 13
Mask use ................................................................................................................................................................. 13

Type of mask used by the general public ................................................................................................................... 20
Mask use during physical activity ............................................................................................................................ 26
Mask use by children .............................................................................................................................................. 27

Introduction ........................................................................................................................................................... 28
Age specific recommendations ............................................................................................................................... 30
Special populations ............................................................................................................................................... 39
Implementation considerations for use of masks in schools ..................................................................................... 40

Home care for patients ........................................................................................................................................... 40
Water, sanitation, hygiene, and waste management ............................................................................................... 41

Authorship, contributors and acknowledgements .................................................................................................. 42
Annexes ................................................................................................................................................................. 46
References ............................................................................................................................................................... 48
Executive Summary


What are these guidelines?
This document is a living guideline that brings together infection prevention and control technical guidance developed and published since the beginning of the COVID-19 pandemic. This consolidated "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline" aims to provide users with the latest evidence-based recommendations for infection prevention and control in the context of COVID-19 in health care and community settings. The WHO living guidance is separated into two parts: 1) IPC in health care settings in the context of COVID-19 and 2) IPC in community settings in the context of COVID-19. This second edition of the Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline provides the most up-to-date technical guidance on mask use by children.

Each country is facing a different situation in the pandemic depending on a number of factors including the intensity of SARS-CoV-2 circulation, amount of population level immunity, capacities to respond and agility to adjust measures. As the pandemic continues and the virus evolves, changes in transmission intensity, the circulating variant of concern, the capacities for health systems to respond based on the situation will result in need for policy adjustments related to IPC and Public Health and Social Measures. National policies should be evidence based, agile and adjusted as needed taking into consideration these and other factors.

Target Audience
These guidelines are written and intended for policy and decision-makers, public health professionals, infection prevention and control professionals at both the national and facility levels, health care facility administrators, managers and health workers.

How are these guidelines developed?
Guideline development groups (GDG) consisting of experts in infection prevention and control, including health care providers, balanced according to geographical and gender representation, were convened. Different GDGs were used to address specific settings or populations. Potential conflicts of interest were identified and managed appropriately. More details are described in the Authorship, contributors and acknowledgement section. Draft guidelines were circulated to external reviewers. A methodologist with expertise in guideline development complemented the technical expertise of the GDG to support the formulation of recommendations. These guidelines were developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) processes and Evidence to Decision framework (EtD). Details are described in the Methodology section.

With support from the World Health Organization (WHO) Quality Assurance of Norms and Standards department, rapid systematic reviews of published literature were identified for review. Due to the rapidly evolving nature of the pandemic, preprints were included in the evidence synthesis. Where required, additional systematic reviews were conducted by WHO staff or commissioned externally to address specific questions. Details are described in the Methodology section.

This document takes into consideration the evolving epidemiological situation and the emergence of variants of concern (VOC) including Omicron and other factors such as population immunity, availability and uptake of vaccines, the current epidemiology and the evolving context of COVID-19. Further information on Omicron can be found in the technical document Enhancing response to Omicron SARS CoV-2 variant: Technical brief and priority actions for Member States, issued by WHO on 21 January 2022 [1]. MAGICapp was selected to disseminate and update this guideline because of its user-friendly format, structure, and navigation, and the fact that it is well adapted to accommodate the dynamic nature of the COVID-19 public health emergency.

Key updates in this version
The previously published technical guidance documents incorporated in Version 2.0 are as follows.

   This document was integrated into version 1.0 of the COVID-19 infection prevention and control living guideline: mask use in community settings updated in December 2021[3].

   WHO and UNICEF jointly developed this guideline. Advice on the use of masks for children in the context of COVID-19 was first published in August 2020 as an annex to the document Mask use in the context of COVID-19 [2][4]. In December 2021 it was incorporated into the online version 1.0 of the COVID-19 infection prevention and control living guideline: mask use in community settings published using the MAGICapp platform.
In version 2.0 of the living guidance, WHO and UNICEF have jointly developed updated guidelines for mask use by children, including new and updated recommendations for mask use by children of different ages, accommodations for children living with disabilities and updated implementation considerations, including for school settings. The emergence of variants of concern (e.g. Alpha, Beta, Gamma, Delta and Omicron), the continued virus evolution and potential future VOCs, evolving evidence on effectiveness of masks in community settings and transmission of SARS-CoV-2 prompted the updates to this guideline.

**Key points for this updated version for mask use by children in the context of COVID-19 include:**

- The utilization of masks in community settings is likely associated with a decreased risk of SARS-CoV-2 infections compared with no mask-wearing, although there is very limited evidence in children five years and under.
- Masks are not required for children aged 5 years and under.
- In areas where there is known or suspected community transmission of SARS-CoV-2, masks are recommended for use in children ages 6-11 years in the following settings:
  - in indoor settings where ventilation is known to be poor or cannot be assessed, or the ventilation system is not properly maintained, regardless of whether physical distancing of at least 1 metre can be maintained,
  - in indoor settings that have adequate ventilation if physical distancing of at least 1 metre cannot be maintained.
- Adolescents 12 years or older should follow the same WHO recommendations for mask use as adults.
- Children with cognitive or respiratory impairments, developmental disorders, disabilities or other specific health conditions who experience difficulties wearing a mask or have health conditions that interfere with mask-wearing should not be required to wear a mask.
- The use of a medical mask is recommended for children with a higher risk of severe complication from COVID-19 but should be assessed in consultation with the child’s medical provider.

**Definitions**

A *child* is defined as any person under the age of 18 years [5].

*Health workers* are all people primarily engaged in actions with the primary intent of enhancing health. This includes health service providers, such as doctors, nursing and midwifery professionals, public health professionals, technicians (laboratory, health, medical, and non-medical), personal care workers, healers, and practitioners of traditional medicine. It also includes health management and support workers, such as cleaners, drivers, hospital administrators, district health managers, social workers and other occupational groups in health-related activities. This group includes those who work in acute care facilities and long-term care, public health, community-based care and other occupations in the health and social care sectors [6].

*Medical masks* are a type of medical device covering the mouth and nose of the wearer used to prevent the spread of respiratory infections. To be designated as a ‘medical’ or ‘surgical’ mask, the mask must be tested at independent, accredited laboratories and must meet performance standards defined by various internationally recognized standards’ organizations (e.g. European Standards, ASTM, Guobiao, or equivalent). [7].

*Non-medical masks* are a type of facial covering of the mouth and nose of the wearer used to mitigate the spread of respiratory infections which does not meet the performance standards of ‘medical’ or ‘surgical’ masks. Their primary purpose is for source control and to provide a degree of particulate filtration to reduce the amount of inhaled particulate matter. Essential parameters for the performance and safety of non-medical masks have been advocated during the COVID-19 Public Health Emergency of International Concern through several existing international guidelines (e.g. Association Française de Normalisation, World Health Organization, European Committee for Standardization, Bangladesh Directorate General of Drug Administration) and one international standard for non-medical masks (ASTM F3502-21) [7][8][9][10][11]. Non-medical masks which are self-made or commercially produced and do not meet guideline supported essential parameters are permitted in areas which have not mandated minimum performance requirements for non-medical masks prior to sale and use by the general public.

**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGP</td>
<td>Aerosol generating procedure</td>
</tr>
<tr>
<td>aOR</td>
<td>Adjusted odds ratio</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus disease 2019</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CT</td>
<td>Community transmission</td>
</tr>
<tr>
<td>DOI</td>
<td>Deceleration of interest</td>
</tr>
<tr>
<td>EtD</td>
<td>Evidence to decision</td>
</tr>
<tr>
<td>FFP</td>
<td>Filtering facepiece respirator</td>
</tr>
<tr>
<td>GDG</td>
<td>Guideline Development Group</td>
</tr>
<tr>
<td>GPS</td>
<td>Good practice statement</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of Recommendations, Assessment, Development and Evaluations</td>
</tr>
<tr>
<td>ILI</td>
<td>Influenza-like illness</td>
</tr>
<tr>
<td>IPA</td>
<td>International Paediatric Association</td>
</tr>
<tr>
<td>IPC</td>
<td>Infection prevention and control</td>
</tr>
<tr>
<td>NIOSH</td>
<td>National Institute for Occupational Safety and Health</td>
</tr>
<tr>
<td>MAGIC</td>
<td>Magic Evidence Ecosystem Foundation</td>
</tr>
<tr>
<td>OR</td>
<td>Odds ratio</td>
</tr>
<tr>
<td>PICO</td>
<td>Population, intervention, comparator, outcome</td>
</tr>
<tr>
<td>PPE</td>
<td>Personal protective equipment</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized control trial</td>
</tr>
<tr>
<td>PHSM</td>
<td>Public health and social measures</td>
</tr>
<tr>
<td>SARS-CoV</td>
<td>Severe acute respiratory syndrome coronavirus</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>Severe acute respiratory syndrome coronavirus 2</td>
</tr>
<tr>
<td>UNICEF</td>
<td>United Nations Children's Fund</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>VE</td>
<td>Vaccine effectiveness</td>
</tr>
<tr>
<td>VOC</td>
<td>Variant of concern</td>
</tr>
</tbody>
</table>
Methodology

Guideline development groups and external review groups
GDGs were convened to review the available evidence and determine the recommendations and good practice statements (GPS) found in this document. GDGs consisted of individuals with broad expertise spanning multiple specialties, across all WHO regions, and were gender-balanced (See Authorship, contributors and acknowledgements). Consensus was sought for recommendations and good practice statements. When consensus was not achieved, approval of a recommendation or good practice statement required a majority (>70%) of the GDG. The technical officer who leads the development of the guidelines collects the required declaration of interests (DOI) from GDG members and assesses them for any potential conflicts. If a conflict of interest is identified, appropriate actions are taken in accordance with the WHO Handbook for guideline development and WHO Guidelines for DOI for WHO Experts. These include removal from the GDG or recusal from voting or discussion for a particular recommendation or a decision to take no action. Members of the GDGs and any DOIs declared are detailed in the Authorship, contributors and acknowledgement section. External review group members were also identified for specific technical areas and engaged for additional review of the guidelines. External review groups do not change the recommendations made by the GDG, but major concerns were brought back to the GDG for additional discussion.

Evidence synthesis and assessment
Given the dynamic situation of the COVID-19 pandemic, this living guideline integrates existing guidance that was developed using streamlined processes. As noted in the Summary, with support from the WHO Quality Assurance of Norms and Standards department, rapid systematic reviews of published literature were identified for review. Because of the time lag for peer-reviewed publication of relevant studies in the context of a dynamic pandemic, preprints were included in the evidence synthesis. In addition, for some topics, systematic reviews were commissioned to external groups (clinical effectiveness of mask use in health care and community settings) or conducted by WHO staff (ecological studies on the effectiveness of masks). These reviews have been published and are regularly updated to identify any emerging evidence that may inform deliberations by the GDG.

Evidence from randomized control trials (RCT) has been limited. Therefore, the reviews also included non-randomized studies. The review on clinical effectiveness focused on cohort and case-control studies. The review of ecological studies also included before-after studies. The systematic reviews presented in GDG meetings were supplemented by other (non-systematically reviewed) data presented by WHO staff, Member States, or partner organizations. Such presentations informed considerations regarding contextual factors on mask recommendations, such as data on the changing epidemiology of COVID-19, mask filtration properties and technical specifications, ventilation, values/preferences, acceptability and feasibility. The literature for each identified topic is assessed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE) to determine the certainty of the evidence (see Table 1), based on the presence of risk of bias/study limitations, inconsistency, imprecision, indirectness and publication/reporting bias.

Table 1. Determining the Quality of Evidence in GRADE

<table>
<thead>
<tr>
<th>Quality level</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>The Group is very confident in the estimate of effect and considers that further research is very unlikely to change this confidence.</td>
</tr>
<tr>
<td>Moderate</td>
<td>The Group has moderate confidence in the estimate of effect and considers that further research is likely to have an important impact on that confidence and may change the estimate.</td>
</tr>
<tr>
<td>Low</td>
<td>The Group has low confidence in the estimate of effect and considers that further research is very likely to have an important impact on that confidence and is likely to change the estimate.</td>
</tr>
<tr>
<td>Very low</td>
<td>The Group is very uncertain about the estimate of the effect.</td>
</tr>
</tbody>
</table>

Process for developing recommendations
Once the certainty of the evidence is determined, the GDG, with the guidance of the Methodologist, determines if a recommendation (strong or conditional) or a good practice statement (GPS) is warranted. GRADE evidence profiles contain an assessment of the certainty of the evidence and a summary of findings for each critical outcome and each key question. The GDG uses these summaries as the basis for discussions and formulation of recommendations.

The Evidence to Decision (EtD) framework is used by the GDG to support the formulation of the recommendation or GPS. Core domains in the EtD framework are the balance of benefits and harms and quality of the evidence, although other factors also influence the
recommendations (see table 2). For some domains, there is insufficient published data to provide the GDG with informative systematic reviews or studies of health workers, patients or community members’ perceptions or experience with implementation of IPC recommendations during the pandemic. In such cases, additional evidence/data is presented when available, supplemented by GDG members’ (including community members) experiences and judgements. Strong recommendations are supported when benefits highly outweigh harms with high certainty, the recommendations are not sensitive to variability in preferences/values regarding outcomes, and the recommendations are widely feasible and acceptable, cost-savings or cost-effective, and would improve equity. When certainty is low or very low strong recommendations can be made but they require a strong rationale for potential net benefits and the other EtD domains. In these situations, good practice statements are considered (see the section on GPS). In some situations, after determining that benefits of an intervention do not outweigh harms, and considering EtD domains (certainty of evidence, costs, feasibility, acceptance, preferences), the GDG may make a recommendation against an intervention.

The GRADE tables can be found in the Annex section of this living guidance.

The recommendations on mask use by children were additionally informed by five consultation sessions conducted by the United Nations Children’s Fund (UNICEF) with members of the International Paediatric Association (IPA) members from different geographical regions, in multiple languages, to synthesize paediatric health professionals’ field experiences with the implementation of the previous guidance.

Table 2. EtD framework

<table>
<thead>
<tr>
<th>Domain</th>
<th>Favours strong recommendations</th>
<th>Favours conditional recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance of benefits and harms</td>
<td>Benefits highly outweigh harms</td>
<td>Benefits and harms more closely balanced</td>
</tr>
<tr>
<td>Quality of evidence</td>
<td>Higher certainty</td>
<td>Lower certainty</td>
</tr>
<tr>
<td>Values/preferences regarding outcomes</td>
<td>Benefits to harms assessment not impacted by variability in values/preferences</td>
<td>Variability in values/preferences would impact benefits to harms assessment</td>
</tr>
<tr>
<td>Acceptability</td>
<td>Highly acceptable</td>
<td>Low or variable acceptability</td>
</tr>
<tr>
<td>Costs/Resources</td>
<td>Cost-saving/cost-effective</td>
<td>Costly/cost-ineffective</td>
</tr>
<tr>
<td>Feasibility</td>
<td>Feasible in intended settings</td>
<td>Unfeasible or feasibility varies in intended settings</td>
</tr>
<tr>
<td>Equity</td>
<td>Increased equity</td>
<td>Decreased equity or effect on equity variable</td>
</tr>
</tbody>
</table>

Good practice statements and implementation considerations

Good practice statements are most suitable when benefits are large and harm very small; certainty of benefits and harms are great; the values and preferences are clear; the intervention is cost saving; and the intervention is clearly acceptable, feasible, and promotes equity. GPS characteristically represent situations in which a large and compelling body of indirect evidence, made up of linked evidence including several indirect comparisons, strongly supports the net benefit of the recommended action. GPSs are generally issued due to various reasons including the process, priorities, timeline, resources or nature of the evidence being assessed but is rooted in the fact that answers are obvious. GPSs are not GRADE-d statements [17]. GPSs are not GRADE-d statements.

Implementation considerations are critical elements that facilitate the appropriate use of recommendations and good practice statements but are not GRADE-d. The may be actionable and relevant to implementing one of the intervention options and may include information to enhance implementation of the intervention [18].

Readership cues for statements

The green checkmark and red X symbols reflect statements that were developed using the GRADE evidence assessment methodology and the use of the evidence to decision framework to inform a recommendation or a good practice statement. The grey bar refers to
implementation considerations that support statements through practical advice and are the product of expert consensus.

The GREEN checkmark symbol denotes a recommendation or a good practice statement in favour of an intervention.

The RED X denotes a recommendation or good practice statement against an intervention.

The GREY bar denotes an implementation consideration supporting the practical implementation of the statement.

**Timeline**

Ongoing reviews are being conducted by WHO staff as is the external living systematic review that has been commissioned to continuously monitor emerging evidence on the use of masks in the context of the COVID-19 public health emergency of international concern. New evidence identified in these reviews that could inform revised or new recommendations will trigger reconsideration of the evidence by the GDG. Furthermore, as the pandemic evolves, changes in transmission intensity, circulating variants of concern and capacities for health systems to respond based on the situation will result in GDG reviews of IPC and Public Health and Social Measures.
Part 1: Health care settings (coming soon)
The document "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline" brings together IPC technical guidance developed and published since the beginning of the COVID-19 pandemic. This consolidated document aims to provide users with the latest evidence-based recommendations, through the MAGICapp platform, as a way to easily navigate guidelines in the dynamic context of COVID-19. Many parts of the technical guidance related to Part 1: Health care settings are currently under review. Links to the most recent publication of the technical guidance are available in the sections that follow. Updated guidelines on health care settings will be available in this living guideline in the near future.

What is an IPC program? (coming soon)

Environmental cleaning

The most up-to-date technical guidance for "Cleaning and disinfection of environmental surfaces in the context of COVID-19: interim guidance" was published 15 May 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

Home care for patients

The most up-to-date guidance for "Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance" was published 12 August 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

IPC when COVID-19 is suspected or confirmed

The most up-to-date technical guidance for "Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed: interim guidance" was published 12 July 2021. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

IPC principles and procedures for COVID-19 vaccination activities

The most up-to-date technical guidance for "Aide-memoire: infection prevention and control (IPC) principles and procedures for COVID-19 vaccination activities" was published 15 January 2021. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

Long term care facilities

The most up-to-date guidance for "Infection prevention and control guidance for long-term care facilities in the context of COVID-19: interim guidance" was published 21 March 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

Mask use

The most up-to-date technical guidance for "WHO recommendations on mask use by health workers, in light of the Omicron variant of concern: WHO interim guidelines" was published 22 December 2021. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".
PPE Technical Specifications

Pertinent sections of the technical guidance, "Technical specifications of personal protective equipment for COVID-19", published 13 November 2020, will soon be incorporated in this living guidance.

Prevention, identification and management of health worker infection

The most up-to-date technical guidance for "Prevention, identification and management of health worker infection in the context of COVID-19: interim guidance" was published 30 October 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

Rational use of PPE and considerations during severe shortages

The most up-to-date technical guidance for "Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages" was published on 23 December 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

Risk assessment and management of exposure

The most up-to-date technical guidance for "Risk assessment and management of exposure of health care workers in the context of COVID-19: interim guidance" was published 19 March 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

Safe dead body management

The most up-to-date guidance for "Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance" was published 4 September 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

Water, sanitation, hygiene, and waste management

The most up-to-date technical guidance for "Water, sanitation, hygiene, and waste management for SARS-CoV-2, the virus that causes COVID-19" was published 29 July 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".
Part 2: Community settings

Many of the existing technical guidance documents that will be integrated into this section are under review. Updated versions will be available in future versions. This section includes updated guidelines for mask use by the general public in community settings and mask use by children. Sections that are pending updates have links to the most recent iteration of relevant IPC guidance published online.

Introduction to public health and social measures

What are public health and social measures?
Public health and social measures (PHSMs) are being implemented across the world to suppress SARS-CoV-2 transmission and reduce mortality and morbidity from COVID-19. PHSMs include personal protective measures (e.g. physical distancing, avoiding crowded settings, hand hygiene, respiratory etiquette, mask-wearing); environmental measures (e.g. cleaning, disinfection, ventilation); surveillance and response measures (e.g. testing, genetic sequencing, contact tracing, isolation, and quarantine); physical distancing measures (e.g. regulating the number and flow of people attending gatherings, maintaining distance in public or workplaces, domestic movement restrictions); and international travel-related measures. In this context, it does not include medical countermeasures such as drug administration or vaccination. PHSMs act in concert, and a combination of measures is required to ensure adequate control. Measures should be implemented by the lowest administrative level for which situational assessment is possible and tailored to local settings and conditions. For more information, please refer to the Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [19].

Who are these recommendations intended for?
These guidelines are intended for policy and decision-makers, public health professionals and infection prevention and control professionals at national and facility levels.

Safe dead body management

The most up-to-date guidance for "Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance" was published 4 September 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".

Mask use

Mask management
For any type of mask, appropriate use, storage, cleaning or disposal are essential to ensure that they are as effective as possible and to avoid any increased risk of transmission. Adherence to correct mask management practices varies, reinforcing the need for appropriate messaging [20]. WHO provides the following guidance on the correct use of masks:

- Wash hands thoroughly before putting on the mask.
- Inspect the mask for tears or holes, and do not use a damaged mask.
- Place the mask carefully, ensuring it covers the mouth and nose, adjust to the nose bridge and tie it securely to minimize any gaps between the face and the mask. If using ear loops, ensure these do not cross over as this widens the gap between the face and the mask.
- Avoid touching the mask while wearing it. If the mask is accidently touched, wash hands thoroughly.
- Remove the mask using the appropriate technique. Do not touch the front of the mask; rather, untie it from behind.
- Replace the mask as soon as it becomes damp with a new, clean and dry mask.
- Either discard the mask or place it in a clean plastic resealable bag where it is kept until it can be washed and cleaned. Do not store the mask around the arm or wrist or pull it down to rest around the chin or neck.
- Wash hands immediately after discarding a mask.
- Do not reuse single-use masks.
- Discard single-use masks after each use and properly dispose of them immediately upon removal.
- Do not remove the mask to speak.
- Do not share your mask with others.
• Wash fabric masks in soap or detergent and preferably hot water (at least 60° Centigrade/140° Fahrenheit) at least once a day. If it is not possible to wash the masks in hot water, then wash the mask in soap/detergent and room-temperature water, followed by boiling the mask for 1 minute.
• A mask should be changed to a clean mask at least once daily.

For more information on mask technical specifications, review the following technical document - “Technical specifications of personal protective equipment for COVID-19”, published 13 November 2020

---

**Practical Info**

For information on assessing and improving indoor ventilation, please see WHO's Roadmap to improve and ensure good indoor ventilation in the context of COVID-19.

**Practical considerations for policy-makers:**

The potential advantages of mask use by healthy people in the general public include:

• reduced spread of potentially infectious aerosols or droplets from exhaled breath, including from infected people before they develop symptoms [31];
• encouraging concurrent transmission prevention behaviours such as washing hands and not touching the eyes, nose and mouth [32][33][34]; and
• preventing transmission of other respiratory illnesses such as tuberculosis and influenza and reducing the burden of these diseases during the pandemic. [35].
The potential disadvantages of mask use by healthy people in the general public include:

- headache and/or breathing difficulties, depending on the type of mask used [36];
- development of facial skin lesions, irritant dermatitis or worsening acne when used frequently for long hours [37][38];
- difficulty with communicating clearly, especially for persons who are deaf or have poor hearing or use lip reading [39][40];
- poor compliance with mask-wearing, in particular by young children [41][42][43][44];
- waste management issues; improper mask disposal leading to increased litter in public places and environmental hazards [45]; and
- further disadvantages for, or difficulty wearing masks by, certain members of the population, especially: children; developmentally challenged people; those with mental illness or cognitive impairment; those with asthma, chronic respiratory or breathing problems; those who have had facial trauma or recent oral maxillofacial surgery; and those living in hot and humid environments [36][42].

Evidence To Decision

Benefits and harms

The utilization of masks in community settings is likely associated with a decreased risk of SARS-CoV-2 infections compared with no mask-wearing. SARS-CoV-2 B.1.617.2 (Delta) variant has been reported to have increased transmissibility [21][22][23][24][25]; most GDG members, therefore, agreed that, in the context of the Delta variant, the benefits of mask-wearing in the community setting outweigh potential harms. Ecological studies have identified an association with decreased number of confirmed cases of COVID-19 and policies requiring the use of masks [26][27][28]. A cluster randomized controlled trial evaluating mask promotion (as an indirect public health intervention) found that in a country with low mask use, mask promotion increased mask use and decreased symptomatic SARS-CoV-2 seroprevalence [29]. Conversely, another randomized controlled trial found no statistical significance associated with surgical mask use and a reduced risk of SARS-CoV-2 [30]. The study provided an imprecise estimate for mask utilization verse no utilization; however, the study was not designed to evaluate the effectiveness of mask use for source control.

Many GDG members note that, even though the certainty of the evidence is moderate, there is a substantial need for WHO to produce cohesive and robust recommendations, as the net benefits of mask use by the general public outweigh the potential harms.

Certainty of the Evidence

Balance of desirable and undesirable outcomes.

Preference and values

Discussions with stakeholders and IPC GDG members have indicated a general preference to favour mask use in community settings. Many GDG members note that, in the context of the Delta variant and other variants of concern, masking is a vital SARS-CoV-2 mitigation measure. Members expressed a need to document a clear opinion on the use of masks in community settings, given the impact of local and national values and preferences on IPC policies. Given the availability of masks, community masking is likely feasible.

Resources and other considerations

Many GDG members noted the global supply chain for mask manufacturing has improved and would not pose a severe obstacle to community masking. The cost of both medical masks and non-medical (fabric) masks are relatively low, and do not pose a substantial barrier for low- and middle-income countries.

Gaps in knowledge and research needs
Justification

GDG members were asked to evaluate the strength of the proposed recommendation (strong recommendation versus conditional recommendation). Based on the available evidence, the GRADE process and the Evidence to Decision framework, the IPC GDG agreed on a strong recommendation. The opinion of the GDG was solidified via an online survey, in which 82.1% (23/28) of GDG members voted for a strong recommendation and 17.9% (5/28) voted for a conditional recommendation.

Good practice statement

In settings where there is community or cluster transmission of SARS-CoV-2, policies should be developed, strengthened and implemented to encourage appropriate adherence to a comprehensive package of preventive measures to reduce transmission (ventilation, physical distance, hand hygiene, and respiratory etiquette) including in particular, mask adherence by the general public.

Published 22 December 2021.

Justification

GDG members were initially asked if WHO should develop a statement on the importance of mask-wearing and/or interventions to improve adherence to mask-wearing guidance; however, many members thought it was essential to consider the "bundle" of public health social measures that pertain to the general public. The above good practice statement was determined by an online vote, where 27 GDG members responded, with 55.6% (15) voting for the statement as mentioned above, while the remaining 44.4% (12) voted for slightly different wording for the good practice statement.

Mask use for those with a higher risk of severe complications from COVID-19

Good practice statement

Individuals/people with a higher risk* of severe complications from COVID-19 should wear a medical mask where physical distancing of at least 1 metre cannot be maintained.

* High-risk populations are defined as: people aged ≥ 60 years; or people with underlying comorbidities, such as cardiovascular disease or diabetes mellitus, chronic lung disease, cancer, cerebrovascular disease, immunosuppression, obesity or asthma.

Published 22 December 2021.
Justification

The decision to formalize the above statement as a good practice statement was reached through online voting. Thirty-one members responded; 19 (61.3%) voted to endorse the aforementioned statement as a good practice statement, and the remaining 12 (38.7%) members suggested that the statement should be considered an implementation consideration. Many GDG members noted that those at high risk of sequelae should use reputedly manufactured masks, as there are discrepancies in the effective filtration, fit and breathability of non-medical masks, without quality control testing. GDG members thoroughly discussed advocating the use of medical masks for vulnerable populations, as they are intended for disposal after single use reducing both the risk of self-contamination and the eventual breakdown of effective filtration efficiency inherent with masks that are washed for reuse. GDG members indicated apprehension towards the statement, given concerns of excessive waste and environmental implications.

In all transmission scenarios of SARS-CoV-2

<table>
<thead>
<tr>
<th>Implementation consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>In areas with known or suspected sporadic transmission, or no documented transmission, WHO advise that decision-makers should apply a risk-based approach focusing on the following criteria when considering the use of masks for the general public:</td>
</tr>
<tr>
<td>• purpose of mask use;</td>
</tr>
<tr>
<td>• risk of exposure to SARS-CoV-2;</td>
</tr>
<tr>
<td>• vulnerability of the mask wearer/population;</td>
</tr>
<tr>
<td>• setting in which the population lives;</td>
</tr>
<tr>
<td>• feasibility;</td>
</tr>
<tr>
<td>• type of mask;</td>
</tr>
<tr>
<td>• vaccination coverage; and</td>
</tr>
<tr>
<td>• circulating variants of concern.</td>
</tr>
</tbody>
</table>

Published 22 December 2021.

Justification

GDG members noted the importance of including vaccination coverage and circulating variants of concern to the implementation considerations given the availability of vaccination and the current landscape of SARS-CoV-2 transmission.
In any transmission scenario, persons with any symptoms suggestive of COVID-19 should wear a medical mask and additionally:

- self-isolate and seek medical advice as soon as they start to feel unwell with potential symptoms of COVID-19 (even if symptoms are mild);
- follow instructions on how to put on, take off and dispose of medical masks and wash hands thoroughly [46];
- follow all additional measures, in particular, respiratory hygiene, frequent hand washing and maintaining a physical distance of at least 1 metre from other persons [47].
- If a medical mask is not available for individuals with suspected or confirmed COVID-19, a fabric mask with fit, filtration and breathability assessed to meet WHO's essential parameters for non-medical masks should be worn by patients as a source control measure, pending access to a medical mask. The use of a non-medical mask can minimize the projection of respiratory particles from the user [48][49]

Asymptomatic persons who test positive for SARS-CoV-2 should wear a medical mask when with others for a period of 10 days after testing positive.

Evidence on the protective effect of mask use in community settings

At present, there is only limited and inconsistent scientific evidence to support the effectiveness of masking healthy people in the community to prevent infection with respiratory viruses, including SARS-CoV-2 [15]. A large randomized community-based trial in which 4862 healthy participants were divided into a group wearing medical/surgical masks and a control group found no difference in infection with SARS-CoV-2 [30]. A recent systematic review found nine trials (of which eight were cluster-randomized controlled trials in which clusters of people, versus individuals, were randomized) comparing medical/surgical masks versus no masks to prevent the spread of viral respiratory illness. Two trials involved healthcare workers and seven had community-based participants. The review concluded that wearing a mask may make little or no difference to the prevention of ILI (RR: 0.99; 95% CI: 0.82–1.18) or laboratory-confirmed influenza (LCI) (RR: 0.91; 95% CI: 0.66–1.26) [50]; the certainty of the evidence was low for ILI, moderate for LCI.

By contrast, a small retrospective cohort study from Beijing found that mask use by entire families before the first family member developed COVID-19 symptoms was 79% effective in reducing transmission (odds ratio (OR): 0.21; CI 0.06-0.79) [28]. A case-control study from Thailand found that wearing a medical or non-medical mask all the time during contact with a COVID-19 patient was associated with a 77% lower risk of infection (adjusted odds ratio (aOR) 0.23; 95% CI 0.09–0.60). Several small observational studies with epidemiological data have reported an association between mask use by an infected person and the prevention of onwards transmission of SARS-CoV-2 infection in public settings [26][51][52][53][54].

A number of studies, some peer-reviewed but most published as pre-prints, reported a decline in the number of COVID-19 cases associated with face mask use by the public, using country- or region-level data [47][55][56][57][58][59] [60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75]. One study reported an association between community mask-wearing policy adoption and increased movement (less time at home, increased visits to commercial locations) [76]. These studies differed in setting, data sources and statistical methods, and have important limitations to consider [77], notably the lack of information about actual exposure risk among individuals, adherence to mask-wearing and the enforcement of other preventive measures [78][79].

Studies of influenza, ILI and human coronaviruses (not including COVID-19) provide evidence that the use of a medical mask can
Practical Info

Persons who cannot tolerate a medical mask should rigorously apply respiratory hygiene (i.e., cover mouth and nose with a disposable paper tissue when coughing or sneezing and dispose of it immediately after use; or use respiratory etiquette via coughing or sneezing into a bent elbow covering the mouth and nose, and then wash hands thoroughly).

Prevention and values

Persons with suspected COVID-19 or mild COVID-19 symptoms should wear a medical mask as much as possible, especially when there is no alternative to being in the same room with other people.

Caregivers of or those sharing living space with people with suspected COVID-19 or with mild COVID-19 symptoms should wear a medical mask when in the same room as the affected person.

<table>
<thead>
<tr>
<th>Transmission scenario</th>
<th>Situations/settings (where)</th>
<th>Target population (who)</th>
<th>Mask type (which one)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In settings where there is known or suspected community or cluster transmission of SARS-CoV-2, irrespective of vaccination status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indoor settings where ventilation is known to be poor or cannot be assessed or the ventilation system is not adequately maintained regardless of whether physical distancing of at least 1 metre can be maintained</td>
<td>The general population in public settings such as shops, shared workplaces, schools, churches, restaurants, gyms, etc. or in enclosed settings such as transportation</td>
<td>Non-medical mask</td>
<td></td>
</tr>
<tr>
<td>Indoor settings that have adequate ventilation** if physical distancing of at least 1 metre cannot be maintained</td>
<td>For households, in indoor settings, when there is a visitor who is not a member of the household</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outdoor settings where physical distancing of at least 1 metre cannot be maintained</td>
<td>Individuals/people with a higher risk of severe complications from COVID-19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Settings where physical distancing of at least 1 metre cannot be maintained, and the individual is of increased risk of severe complications</td>
<td>Individuals/people with a higher risk of severe complications from COVID-19</td>
<td>Medical mask</td>
<td></td>
</tr>
<tr>
<td><strong>Known or suspected sporadic transmission or no documented SARS-CoV-2 transmission</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk-based approach</td>
<td>General Population</td>
<td>Depends on purpose</td>
<td></td>
</tr>
<tr>
<td><strong>Any transmission scenario</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any setting in the community</td>
<td>Anyone with suspected or confirmed COVID-19, regardless of whether they have symptoms or not. OR Anyone awaiting viral test results when in the presence of others</td>
<td>Medical mask</td>
<td></td>
</tr>
</tbody>
</table>

Published 22 December 2021
Implementation consideration for policy-makers, when providing guidance, or setting standards for manufacturers on type of mask used by the general public

The following mask types are acceptable options for use by the general public:

- reusable non-medical masks that comply with standards*;
- disposable medical masks, if the availability of medical masks meeting minimum performance criteria for health workers has been assured**;
- if the above options are not available, other types of well-fitting non-medical masks*** are an acceptable option (according to local policies).

*Complying with the ASTM F3502 standard or CEN Working Agreement 17553, or a non-medical mask meeting WHO essential parameters (see practical info for more information).

**Complying with medical mask standards EN 14683 Type I, ASTM F2100 Level 1, YY/T 0969, YY 0469 (or equivalent).

***Including homemade multi-layered masks (see more info for more information).

Published 22 December 2021.

### Practical Info

**Table 2. Essential parameters (minimum and preferred thresholds) for manufactured non-medical mask**

<table>
<thead>
<tr>
<th>Essential Parameters</th>
<th>Minimum threshold</th>
<th>Preferred threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Filtration</strong>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 Filtration</td>
<td>70% at 3 µm</td>
<td>&gt;50% at 0.3 µm, without compromising breathability</td>
</tr>
<tr>
<td>efficiency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2. Challenge particle</td>
<td>Solid: sodium chloride (NaCl), Talcum powder, Holi powder, dolomite, Polystyrene Latex spheres</td>
<td>Solid: sodium chloride (NaCl), Polystyrene Latex spheres</td>
</tr>
<tr>
<td></td>
<td>Liquid: DEHS Di-Ethyl-Hexyl-Sebacat, paraffin oil</td>
<td></td>
</tr>
<tr>
<td>1.3. Particle size</td>
<td>Choose either size: 3 µm, 1 µm, or smaller</td>
<td>0.3 µm</td>
</tr>
<tr>
<td><strong>2. Breathability</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1. Breathing</td>
<td>≤60 Pa/cm²</td>
<td>Adult: ≤ 40 Pa/cm²</td>
</tr>
<tr>
<td>resistance**</td>
<td></td>
<td>Children: ≤ 20 Pa/cm²</td>
</tr>
<tr>
<td>2.2 Exhalation valves</td>
<td>Not recommended</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>3. Fit</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 3.1. Coverage

Full coverage of nose and mouth, consistent, snug perimeter fit at the nose bridge, cheeks, chin and lateral sides of the face; adequate surface area to minimize breathing resistance and minimize side leakage.

Same as current requirements

### 3.2 Face seal

Not currently required

Seal as good as FFR (respirator)

Fit factor of 100 for N95

Maximum Total Inward Leakage of 25% (FFP1 requirement)

OR

Leakage ratio of ≥5

### 3.2. Sizing

Adult and child

Should cover from nose bridge to below the chin and cheeks on either side of the mouth

Sizing for adults and children (6-9, 10-12, >12)

### 3.3 Strap strength

> 44.5 N

* Smaller particles may result in lower filtration.

** High resistance can cause bypass of the filtration layers of the mask. Unfiltered air will leak out the sides or around the nose on the path of least resistance.

### Table 3. Additional (optional) parameters for manufactured non-medical masks

<table>
<thead>
<tr>
<th>Additional parameters</th>
<th>Minimum thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>If reusable, the number of wash cycles</td>
<td>5 cycles</td>
</tr>
<tr>
<td>Disposal</td>
<td>Reusable</td>
</tr>
<tr>
<td>If biodegradable (CFC-BIO), according to UNI EN 13432, UNI EN 14995</td>
<td></td>
</tr>
<tr>
<td>Antimicrobial (bacteria, virus, fungus)</td>
<td>ISO 18184 (virus)</td>
</tr>
<tr>
<td>performance</td>
<td>ISO 20743 (bacteria)</td>
</tr>
<tr>
<td></td>
<td>ISO 13629 (fungus)</td>
</tr>
<tr>
<td></td>
<td>AATCC TM100 (bacteria)</td>
</tr>
<tr>
<td>Chemical safety</td>
<td>Comply with REACH regulation, including inhalation safety</td>
</tr>
</tbody>
</table>

**Standards organizations’ performance criteria**

Manufacturers producing masks with consistent standardized performance can adhere to published, freely available guidance from several organizations including those from ASTM International, the French Standardization Association (AFNOR Group), The European Committee for Standardization (CEN), Swiss National COVID-19 Task Force, the American Association of Textile Chemists and Colorists (AATCC), the South Korean Ministry of Food and Drug Safety (MFDS), the Italian Standardization Body.
Additional performance criteria:

- The non-medical mask, including all components and packaging, must be non-hazardous, non-toxic and child-friendly (no exposed sharp edges, protruding hardware or rough materials).
- Factory-made non-medical masks must be made using a process that is certified to a quality management system (e.g., ISO 9001).
- Social accountability standards (e.g., SA8000) for multiple aspects of fair labour practices, health and safety of the workforce and adherence to UNICEF’s Children’s Rights and Business Principles are strongly encouraged.

**Filtration and breathability**

Filtration depends on the filtration efficiency (in %), the type of challenge particle (oils, solids, droplets containing bacteria) and the particle size (see Table 2). Depending on the fabrics used, filtration and breathability can complement or work against each other. Filtration is dependent on the tightness of the weave, fibre or thread diameter. Non-woven materials used for disposable masks are manufactured using processes to create polymer fibres that are thinner than natural fibres such as cotton, and that are held together by partial melting. Breathability is the difference in pressure across the mask and is typically reported in millibars (mbar) or Pascals (Pa), or normalized to the cm² in mbar/cm² or Pa/cm². Non-medical fabric masks consisting of two layers of polypropylene spunbond and two layers of cotton have been shown to meet the minimum requirements for droplet filtration and breathability of the CEN CWA 17553 guidance. It is preferable not to select elastic material to make masks as the mask material may be stretched over the face, resulting in increased pore size and lower filtration through reuse. Additionally, elastic fabrics are sensitive to washing at high temperatures and may therefore degrade over time.

Coating the fabric with compounds such as wax may increase the barrier and render the mask fluid-resistant; however, such coatings may inadvertently block the pores completely and make the mask difficult to breathe through. In addition to decreased breathability, unfiltered air may more likely escape from the sides of the mask on exhalation. The coating is therefore not recommended.

**Fit: shape and sizing**

Fit is the third essential parameter, and takes into consideration coverage, seal, sizing and strap strength. Fit of masks is currently not defined by any standard except for the anthropometric considerations of facial dimensions (ISO/TS 16976-2) or simplified to height mask (South Korean standard for KF-AD). Ideally, the mask should not have contact with the lips, unless hydrophobic fabrics are used in at least one layer of the mask [81]. Leaks where unfiltered air moves in and out of the mask may be attributed to the size and shape of the mask [82].
Optional parameters for consideration

If reusable:

- the biodegradability;
- antimicrobial performance (where applicable); and
- chemical safety (see Practical Info section).

Non-medical masks intended to be reusable should include instructions for washing and, must be washed a minimum of five cycles, implying initial performance is maintained after each wash cycle. Advanced fabrics may be biodegradable or compostable at the end of service life, according to a recognized standard process (e.g. UNI EN 13432, UNI EN 14995 and UNI/PdR 79).

Manufacturers sometimes claim their non-medical masks have antimicrobial performance. Antimicrobial performance may be the result of coatings or additives to the fabric fibres. Treated fabrics must not come into direct contact with mucous membranes; the innermost fabric should not be treated with antimicrobial additives, only the outermost layer. In addition, antimicrobial fabric standards (e.g. ISO 18184, ISO 20743, AATCC TM100, AATCC 100) are generally slow-acting. The inhibition on microbial growth may not take full effect until after a contact time of 2–24 hours, depending on the standard. The standards have generally been used for athletic apparel and to substantiate claims of odour control performance. These standards are not appropriate for non-medical cloth masks and may provide a false sense of protection from infectious agents. If claims are made, manufacturers should specify the standard that supports antimicrobial performance, the challenge organism and the contact time.

Volatile additives are discouraged as these may pose a health risk when inhaled repeatedly during wear. Certification according to organizations including OEKO-TEX (Europe) or SEK (Japan), and additives complying with REACH (Europe) or the United States Environmental Protection Agency (EPA), indicate that textile additives are safe and added at safe levels.

Justification

GDG members agreed with the notion of standardizing recommendations for the utilization and specifications of masks for the general public. Many GDG members expressed concern of being overly prescriptive while the current state of evidence on the quality and effectiveness of non-medical masks continues to evolve as this may limit the social enterprise of homemade mask production, a standard practice in many WHO member state countries. However, GDG members agreed with laboratory evidence confirming that non-medical masks without standardized quality control processes can have large variabilities in their key parameters (see Practical info section for information on essential parameters for non-medical masks). Members also conveyed the importance of specifying the use of well-fitting masks, as the fit is an essential parameter for effective source control and protection. In addition, GDG members spoke of the potential harms associated with limited resources and lack of personnel to test the essential parameters of masks in various low-income settings, along with expressing concerns regarding waste disposal.

Adaptation

Homemade non-medical masks made from household fabrics (e.g. cotton, cotton blends and polyesters) should ideally have a three-layer structure, with each layer providing a function (see Figure 1) [83].

1. an innermost layer (that will be in contact with the face) of a hydrophilic material (e.g. cotton or cotton blends of terry cloth towel, quilting cotton and flannel) that is non-irritating against the skin and can contain droplets [81];
2. a middle hydrophobic layer of synthetic breathable non-woven material (spunbond polypropylene, polyester and polyaramid), which may enhance filtration, prevent permeation of droplets or retain droplets [81][84]; and
3. an outermost layer made of hydrophilic material (e.g. spunbond polypropylene, polyester or their blends), which may limit external contamination from penetrating through the layers to the wearer’s nose and mouth and maintains and prevents water accumulation from blocking the pores of the fabric [81].
Figure 1. Non-medical mask construction using breathable fabrics such as cotton, cotton blends, polyesters, nylon and polypropylene spunbond that are breathable may impart adequate filtration performance when layered. Single- or double-layer combinations of advanced materials may be used if they meet performance requirements [85].

Although a minimum of three layers is recommended for non-medical masks for the most common fabric used, single, double or other layered combinations of advanced materials may be used if they meet performance requirements.

Assumptions regarding homemade masks are that individual makers only have access to common household fabrics and do not have access to test equipment to confirm target performance (filtration and breathability). Figure 1 illustrates a multi-layer mask construction with examples of fabric options. Very porous materials, such as gauze, even with multiple layers, may provide very low filtration efficiency [86]. Fabrics with higher thread count offer improved filtration performance [87]. Coffee filters, vacuum bags and materials not meant for clothing should be avoided, as they may contain injurious content when breathed in. Microporous films such as Gore-Tex are not recommended [88].
Exhalation valves on respirators and non-medical masks are discouraged as they do not allow for adequate source control from the wearer. Exhalation valves permit bypass of the filtration layers when the wearer exhales, potentially allowing pass-through of infectious particles.


At present, face shields are considered to provide a level of eye protection only, and should not be considered as an equivalent to masks with respect to respiratory protection and/or source control. Current laboratory testing standards only assess face shields for their ability to provide eye protection from chemical splashes [90].


Practical Info

In the context of non-availability or difficulties wearing a non-medical mask (e.g. on people with cognitive, respiratory or hearing impairments), face shields may be considered as an alternative, noting that they are inferior to masks with respect to respiratory particle transmission and prevention. If face shields are to be used, ensure proper design to cover the sides of the face and below the chin.

Mask use during physical activity

WHO advises that people should not wear masks during vigorous-intensity physical activity [85] because masks may reduce the ability to breathe comfortably. The most important preventive measure is to maintain physical distancing of at least 1 metre and to ensure good ventilation when exercising.


Practical Info

When community or cluster transmission of SARS-CoV-2 is experienced in local context, particular attention should be paid to ensuring physical distancing of at least 1 metre between persons outside of their households and frequent cleaning and disinfection of any public environment in which exercise is performed, especially high-touch surfaces. As well, if the activity takes place indoors, adequate ventilation (e.g. 10 litres of air exchange per second, per person occupying an indoor space) should be ensured at all times through natural ventilation or a properly functioning and maintained ventilation system [89]. If all the above measures cannot be ensured, consider temporary closure of public indoor exercise facilities (e.g. gyms).
Evidence To Decision

Benefits and harms

There are limited studies on the benefits and harms of wearing medical masks, respirators and non-medical masks while exercising. Several studies have demonstrated statistically significant deleterious effects on various cardiopulmonary physiologic parameters during mild to moderate exercise in healthy subjects and in those with underlying respiratory diseases [86][87][88][91][92][93]. The most significant impacts have been consistently associated with the use of respirators and in people with underlying obstructive airway pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD), especially when the condition is moderate to severe [88]. Facial microclimate changes with increased temperature, humidity and perceptions of dyspnoea were also reported in some studies on the use of masks during exercise [87][94]. A recent review found negligible evidence of any negative effects of mask use during exercise but noted concern for individuals with severe cardiopulmonary disease [95].

Preference and values

Mask use by children

Guiding Principles

Given the limited evidence on the use of masks by children in the context of COVID-19, including limited evidence on transmission of SARS-CoV-2 in children at specific ages, policy formulation by national authorities should be guided by the following overarching...
principles:

- Do no harm: the best interest, health and well-being of the child should be prioritized.
- The application of these guidelines should not impact development or learning outcomes, including access to education.
- The guidelines should consider the feasibility of implementing recommendations in different social, cultural and geographic contexts, including limited resource and humanitarian settings, and among children with disabilities or specific health conditions.
- Any recommendation for mask use for children should encompass needed flexibility to enable children to maintain their rights to play, to education and ability to engage in everyday activities [5].
- National policies on the use of masks for children should be adapted based on social, cultural and environmental considerations, including in settings with limited resources and humanitarian settings.

Introduction

WHO guidance on the use of masks for children in the community was first published in August 2020 as an annex to the document Mask use in the context of COVID-19 [2][4]. In December 2021, it was incorporated into the online version 1.0 of the WHO IPC COVID-19 living guideline published using the MAGICapp platform [3]. This updated version includes new recommendations for mask use by children of different ages, accommodations for children living with disabilities and updated implementation considerations, including for school settings.

WHO and UNICEF jointly developed this guideline. A guideline development group, the WHO-UNICEF GDG for the use of masks by children in the context of COVID-19, was established. Details on the composition of the GDG and the retrieval, synthesis and assessment of evidence can be found in the methods and acknowledgements sections of the document.

When aiming to reduce community transmission and mitigate the impact of COVID-19 outbreaks on health and social services, policies developed for mask use should be included as one element of a comprehensive package of preventive measures to reduce transmission (ventilation, physical distance, hand hygiene, and respiratory etiquette). In any decision being made related to the use of masks by children, the guiding principles for the best interest of children and a “do no harm” approach should prevail.

Each country is facing a different situation in the pandemic depending on a number of factors including the intensity of SARS-CoV-2 circulation, amount of population level immunity, capacities to respond and agility to adjust measures. As the pandemic continues and the virus evolves, changes in transmission intensity, the circulating variant of concern, and the capacities for health systems to respond based on the situation will result in need for policy adjustments related to IPC and Public Health and Social Measures. National policies should be evidence based, agile and adjusted as needed taking into consideration these and other factors. Countries should conduct an assessment of the transmission scenario and the health system response capacity – and assign a situational level to a geographic area. The assessment should examine quantitative and qualitative information from available sources, and can refer to the situational and community transmission (CT) Levels CT1-CT4 as described in, Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [19]. Additional factors, including population level immunity, will need to be taken into account when setting national and sub-national policies, as outlined above.

This section of the guideline focuses on the use of masks in children in the context of COVID-19 in community settings, such as schools and recreational areas. Children spend a considerable portion of their time in schools, which may have indoor and outdoor areas, and there are existing specific guidance documents available that address school-related public health measures.

Recommendations on types of masks can be found in the mask use in community settings section of the document.

There are five statements for the use of masks by children, including three recommendations by age group (< 5, 6-11, 12 and over), and two good practice statements.

Evaluation

Monitoring and evaluation of the impact of mask use by children

When implementing policies for mask-wearing for children, key information should be collected on a regular basis and where
possible utilized to inform future policy. Monitoring and evaluation should be established at the onset and include:

- indicators that measure the impact on the child’s health, including mental health
- reduction in transmission of SARS-CoV-2 at community and health facility level
- motivators and barriers to mask-wearing
- impacts on children’s development and learning and school attendance
- ability of children to express themselves
- impact on children with developmental delays, health conditions and disabilities or other vulnerabilities
- experiences of children, their needs, perspectives and expectations.

Data should be used to inform policy updates and strategies on:

- communication
- training and support to teachers, educators, parents and children
- distribution of materials that empower children to use masks appropriately
- indicators to lift mask requirements for children.

Analyses should include sex, age and physical, social and economic stratification to ensure that policy implementation reduces health and social inequities.

Research Needs

There are significant limitations in the available evidence on benefits and harms of mask use in children including a lack of evidence on important developmental and long-term outcomes. Future studies should consider evaluation of the effectiveness of mask use by children of different age groups in reducing transmission of SARS-CoV-2, impacts on learning and development, psychological health and quality of life. While RCTs would be ideal, well conducted observational studies that control for other infection control measures, exposures and other confounders would also be informative.
**SARS-CoV-2 Transmission in Children**

Disease severity and mortality due to COVID-19 including infections with VOCs increases with age, and children tend to present with a milder course of illness than older population groups [96][97][98]. The transmission characteristics among children need to be interpreted in light of new VOC’s, in particular, Omicron; vaccination strategies and age-specific vaccination coverage and changes in mixing patterns as a result of the implementation of PHSM. Evidence early in the pandemic from household, serological and infection prevalence studies suggested that young children may be at lower risk of infection than adolescents and adults and potentially transmit SARS-CoV-2 less [96][98][99][100][101][102][103][104][105][106][107][108][109]. However, more recent epidemiological trends seem to indicate that children contribute to transmission similarly to adults, due to their social mixing patterns in some settings and in light of emerging VOC’s such as Omicron [1][110][111][112][113][114]. This has been well documented in settings where extensive community testing has been undertaken (e.g. the REACT study in the United Kingdom) [115]. The European Centre for Disease Prevention and Control (ECDC) reported the age distribution of COVID-19 among children, as of July 2021, in the European Union (EU), European Economic Area (EEA) and the United Kingdom. They found that children made up an increasing proportion of weekly case numbers, with the most noticeable increase among those aged 5-11 years. These findings should be interpreted in light of the proportion of vaccinated adolescents, social mixing patterns by age and adults in those countries at the time [98][110].

Studies from high-income countries have also shown that in some settings, children tend to have more extensive social mixing patterns than adults and consequently more contacts than adults [112]. Thus even though the propensity to transmit may be lower for children, in some settings, they may be contributors to transmission as a consequence of their social mixing patterns, especially if public health and social measures have been relaxed [1][101][102][109][116][117][118][119].

The Omicron variant has resulted in very high levels of incidence in most countries, across all age groups, with higher incidence levels than observed earlier in the pandemic [119]. There is currently limited evidence to suggest a difference in transmission risk of Omicron according to age group, other than that modulated by vaccination, but more data are required.

In the context of the Delta and Omicron VOC increased transmission and growth rates have been documented [119].

---

**Age specific recommendations**

**Recommendation for children 5 years of age and under**

- **Conditional recommendation against**, Very low certainty evidence

  **Masks are not required for children 5 years of age and under**

*Published 7 March 2022*

---

**Practical Info**

**Implementation considerations**

As mask use is not recommended in this age group, IPC and public health and social measures should be prioritized to minimize the risk of SARS-CoV-2 transmission.

- Adults and staff working with children should follow national guidelines for vaccination against COVID-19.
- Adequate ventilation* should be in place and maintained in settings where children are congregating or cared for.
- Adults and staff working with children should wear masks (see WHO recommendations for mask use in adults).
Adequate sanitation and hygiene requirements and a regimen for environmental cleaning and disinfection should be in place in settings where children congregate or are cared for. Children should be taught to perform frequent hand hygiene and respect respiratory etiquette using an age-appropriate approach and materials.

In the event that policymakers decide to adjust the age range for mask recommendations (i.e. children under the age of five years would utilize a mask), relevant settings should have adequate human resources to ensure safe mask use. Adoption of the mask recommendation should include appropriate and consistent supervision by an adult and the ability to ensure mask compliance and adherence, especially if mask-wearing is expected for an extended period. The guiding principles of the best interest of children and a “do no harm” approach should prevail.

*For adequate ventilation refer to regional or national institutions or heating, refrigerating and air-conditioning societies implementing ventilation requirements. If recommendations are not in place, a recommended ventilation rate of 10l/s/person should be met (except in healthcare facilities which have specific requirements). For more information, consult Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [134].

Evidence To Decision

### Benefits and harms

#### Uncertain benefits and harms

The wearing of a well-fitted mask is associated with a decrease in SARS-CoV-2 transmission in the community and provides protective benefits to the individual [14][15][16]. A systematic review on the clinical effectiveness of masks included two RCT and three observational studies in adult populations, which provided some evidence that mask-wearing in the community is associated with decreased risk of COVID-19 infection [15][16][26][27][28][29][30]. The systematic review found inconsistent effects of masks on reducing the risk of influenza-like illness (ILI) in community settings, although a cluster RCT found that hand hygiene and face masks may prevent household transmission of influenza if applied early after symptom onset in an index case [41]. A systematic review evaluating 21 ecological studies in adults reports that mask use is associated with reducing mortality, the incidence of disease, and hospitalization in the community in the context of COVID-19 [14]. Studies from the United States, Spain, Germany and the United Kingdom looked at the effectiveness of mask use in ages 4-18; and eleven studies reported an association between mask use and decreased COVID-19 incidence in children [120][121][122][123][124][125][126][127][128][129][130]. These studies were generally observational and ecological with important shortcomings including limited reporting of other infection control measures and exposures.

The systematic review did not find evidence of serious harms with masks in adults in community settings, although bothersome harms were common. Evidence on potential harms, specifically in children aged five years or younger, is limited. Parents who completed an online survey conducted in France reported behavioural and mood changes (e.g. anxiety, sadness, anguish), headaches, speaking difficulties and breathing discomfort attributed to mask-wearing [131]. There is currently no evidence on the long-term impact of mask use on the physical and mental health, development and wellbeing of children.

Given the lack of direct evidence in this age group, evidence was extrapolated from adults. The GDG found that evidence from adults is less applicable (more indirect) to children five and under compared to older children due to lower COVID-19 incidence and severity. Even if masks are associated with the same relative reduction in COVID-19 incidence in children five and under as in adults, the absolute benefits would be smaller due to lower incidence and severity. Furthermore, benefits in children five and under are likely further reduced due to suboptimal adherence.

Additionally, despite the limited/lack of evidence on harms in this age group, there were concerns regarding potential greater harms with regard to childhood development. The GDG, therefore, determined that given the above information, the benefits of mask-wearing in children aged five and under are trivial to none and do not outweigh potential harms.
The GDG determined that benefits of masks in children <5 years did not outweigh harms. This was based on the low certainty evidence and the lower incidence (and severity) of SARS-CoV-2 transmission in this age group relative to older children and adults. The GDG also considered the low acceptability and preference for mask use and agreed that a recommendation for the use of masks for this age group was not appropriate.

Decisions for children under the age of five years to wear masks may be informed by factors such as contact with high-risk individuals, local incidence of COVID-19, ability to adhere to and tolerate mask-wearing, local vaccination rates and parental preferences. There was agreement among the GDG members that in settings where children of this age group are

Certainty of the Evidence
The evidence certainty is very low due to the limited evidence in this age group and lower applicability of evidence in adults to this age group compared to older children.

Preference and values
The GDG determined that given the close balance of benefits and harms, different preferences (e.g. focusing on potential benefits in terms of reducing infection risk versus focusing on potential developmental harms) could change the decision. Therefore, variability in preferences/values could impact judgments about mask use in this population.

Resources and other considerations
Given that masks are not recommended for this age group, minimal resource implications are anticipated.

Equity
Effect on equity variable
Risk factors that increase the likelihood of contracting COVID-19 include race, ethnicity, and community-level socioeconomic status [132][133].

The GDG assessed effects on equity as uncertain or variable, because masks are not required in this age group, but would depend upon how mask use is implemented. If masks are widely available, using masks could improve equity by reducing the risk of transmission overall, including among socioeconomically disadvantaged groups more impacted by COVID-19. However, there is a need to ensure that lack of access to masks does not negatively impact children (which would decrease equity) and that certain populations (such as disabled individuals) are not adversely impacted.

Acceptability
There is a significant lack of evidence as to the acceptability of mask use for children in this age group across different contexts[135][120]. Additionally, despite limited evidence on harms in this age group, there are concerns regarding potential greater harms with regard to childhood development.

The GDG felt that the acceptability of mask use in children under five years of age is variable.

Feasibility
The GDG judged that use of masks is less feasible in this age group since it requires more supervision and children may have more difficulty wearing masks for prolonged periods and during certain activities.

Justification
The GDG determined that benefits of masks in children <5 years did not outweigh harms. This was based on the low certainty evidence and the lower incidence (and severity) of SARS-CoV-2 transmission in this age group relative to older children and adults. The GDG also considered the low acceptability and preference for mask use and agreed that a recommendation for the use of masks for this age group was not appropriate.

Decisions for children under the age of five years to wear masks may be informed by factors such as contact with high-risk individuals, local incidence of COVID-19, ability to adhere to and tolerate mask-wearing, local vaccination rates and parental preferences. There was agreement among the GDG members that in settings where children of this age group are
Implementation considerations

congregating – for example, childcare settings – it is important to adhere to PHSM and IPC measures including adequate ventilation, hand hygiene and environmental hygiene measures, regardless of whether or not masks are used.

Recommendation for children 6 - 11 years of age

In areas where there is known or suspected community transmission* of SARS-CoV-2, masks are recommended for use in children ages 6-11 years in the following settings:

- in indoor settings where ventilation is known to be poor or cannot be assessed, or the ventilation system is not properly maintained**, regardless of whether physical distancing of at least 1 metre can be maintained***;
- in indoor settings that have adequate ventilation** if physical distancing of at least 1 metre cannot be maintained***.

* Details on the levels of community transmission (CT1-CT4) can be found in Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [19]. Countries should regularly assess the intensity of spread and health systems capacities at the most localized levels possible.

** For adequate ventilation refer to regional or national institutions or heating, refrigerating and air-conditioning societies implementing ventilation requirements. If regulations are not in place, a recommended ventilation rate of 10l/s/person should be met (except in healthcare facilities which have specific requirements). For more information, consult Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [134].

*** Physical distance should be increased beyond 1 metre whenever feasible.

Published 7 March 2022

Practical Info

Countries should regularly assess the intensity of spread and health systems capacities at the most localized levels possible. The assessment should examine the quantitative and qualitative information from available sources and can refer to the situational level (S0-S4) and community transmission (CT) Levels CT1-CT4 as described in Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [19]. Additional factors, including population level immunity, will need to be taken into account when setting national and sub-national policies.

Policy and decision-makers are encouraged to ensure the following considerations are addressed when implementing the use of masks in this age group.

- Factors that can influence the decision on implementing the use of masks include the age range in this group, the impact on education and development, routine activities, equity and the general health and wellbeing of children.
- Masks should be made accessible (free of charge) to children in schools, health care settings and any setting where they congregate (e.g. recreational areas), to ensure all children – including those living in households or geographic areas with social vulnerabilities and limited resources – have equitable access. No child should be denied access to these activities for not wearing a mask.
- Efforts should be made to accommodate children who do not have access to masks or are unable to tolerate a mask so they can participate in activities involving face-to-face gatherings. No child should be denied access to these activities for not wearing a mask.
- Routine mask breaks should be implemented when children are expected to wear masks for a longer duration.
- The child's capacity to adhere to correct mask use and availability of appropriate supervision should be addressed.
especially in younger children within this age group.

- Age-appropriate communication should aim to help the child understand the purpose and proper use of mask-wearing.
- The design of masks for children should take into consideration the safety and overall quality of the material and ensure a proper fit without compromising breathability, comfort and child-friendliness (appropriate size, colours, patterns).
- Key stakeholders should develop and implement strategies for ensuring that each reusable mask is worn by one child and stored safely, for disposal of soiled masks (e.g. in dedicated bags or containers) and addressing the need for masks to be changed when soiled or wet.
- The use of masks is part of a comprehensive package of preventive measures to reduce transmission including ventilation, physical distance, hand hygiene and respiratory etiquette.

Evidence To Decision

**Benefits and harms**

The wearing of a well-fitted mask is associated with a decrease in SARS-CoV-2 transmission in the community and provides protective benefits to the individual [14][15][16]. A systematic review on the clinical effectiveness of masks included two RCT and three observational studies in adult populations that provided some evidence that mask-wearing in the community is associated with decreased risk of COVID-19 infection [15][16]. The systematic review found inconsistent effects of masks on reducing the risk of ILI in community settings, though a cluster RCT found that hand hygiene and face masks may prevent household transmission of influenza if applied early after symptom onset in an index case [41]. A systematic review evaluating 21 ecological studies in adults report that mask use is associated with reducing mortality, the incidence of disease, and hospitalization in the community [14]. Studies from the United States, Spain, Germany and the United Kingdom looked at the effectiveness of mask use in ages 4-18. Ten studies reported an association between mask use and decreased COVID-19 incidence in children. However, these studies were generally observational and ecological with several limitations, including limited reporting of other control measures [121][122][123][124][125][126][127][128][129][130]. Furthermore, two studies of influenza (one RCT and one observational study) found a reduced incidence with mask-wearing in households and school settings [41][44]. The systematic review did not find evidence of serious harms with masks in adults in community settings, although bothersome harms were common. Evidence on potential harms, specifically in children aged 6-11, is limited. Parents who completed an online survey conducted in France - among whom only 9% had children over the age of 11-reported behavioural and mood changes (e.g. anxiety, sadness, anguish), headaches, speaking difficulties and breathing discomfort attributed with mask-wearing [131]. There is currently no evidence on the long-term impact of mask use on the physical and mental health, development and wellbeing of children.

The GDG previously determined that in adults, mask use in community settings is likely associated with a decreased risk of SARS-CoV-2 infections compared with no mask-wearing. The evidence is indirect since it is from adults. Emerging variants such as SARS-CoV-2 B.1.617.2 (Delta) and SARS-CoV-2 B.1.1.529 (Omicron) have been reported to have increased transmissibility [1]. The GDG judged that the benefits in this group are smaller than in adolescents 12 years and older, given lower incidence/severity and reduced adherence (at least in the younger children in this age range).

Evidence on the harms in this age group is also limited. An online survey conducted in France amongst parents of children in a wide age range (<6 years to >11 years) found that parents attributed behavioural change and mood changes (e.g. anxiety, sadness, anguish) headaches, speaking difficulties and breathing discomfort to mask-wearing [131]. However, another study in the United States of America found no apparent adverse biological effects (e.g. impacts on memory, heart rate, oxygen saturation, and emotional state) after mask wearing for at least 30 minutes in elementary school children [136]. There is currently no evidence on the long-term impact of mask use on the physical and mental health, development and wellbeing of children.

The evidence is indirect since it is from adults; the GDG judged that the benefits in this age group are smaller than in
adolescents under 12, given lower incidence/severity and reduced adherence (at least in younger children in this age range). Therefore the GDG judged that the benefits of mask-wearing slightly outweigh the harms. Benefits are likely to be larger in situations in which the risk of infection are higher, e.g. poor ventilation and/or unable to physical distance.

Certainty of the Evidence

There is limited evidence on the benefits and harms of mask-wearing in this age group. Although ecological studies that include children aged 4-18 years have reported an association between mask mandates and a reduced incidence of infection these studies were judged to be low quality, with few studies available from low and middle-income countries [121][122][123][124][125][126][128][129][130][139][140]. Even though this evidence is largely indirect, it was judged by the GDG to have applicability, especially to older children in this group.

Preference and values

Substantial variability in preferences, ideas and values is expected regarding the potential outcomes of mask use (prevention of SARS-CoV-2 infection, side effects). Such differences could have an impact on the decision to use masks in this age group.

The GDG determined that given the close balance of benefits and harms, different preferences (e.g., focusing on potential benefits in terms of reducing infection risk versus focusing on potential harms.) could change the decision. Consequently variability in preferences/values could impact judgments about mask use in this population.

Resources and other considerations

There is no formal data available on costs. Given the widespread availability and relatively low costs of non-medical and medical masks, the GDG judged costs and resource availability to be low.

Equity

Effect on equity variable

Risk factors that increase the likelihood of contracting COVID-19 include race, ethnicity, and community-level socioeconomic status [132][133].

The GDG assessed effects on equity as uncertain or variable as it depends on mask use is implemented. If masks are widely available using masks could improve equity by reducing the risk of transmission overall, including among socioeconomically disadvantaged groups more impacted by COVID-19. However, there is a need to ensure that lack of access to masks does not negatively impact children (which would decrease equity) and that certain populations (disabled individuals) are not adversely impacted.

Acceptability

The limited evidence available indicates variability in the acceptance of masks in children aged 6 to 11. One online study found that parents were generally opposed to children between the ages of 6-10 wearing masks, especially in school settings. Other studies reported that children in this age group demonstrated good adherence to mask-wearing, in particular in school settings [120][128][137].

The GDG decided to make a conditional recommendation despite the low certainty evidence because the benefits of
mask-wearing – reduction of SARS-CoV-2 transmission and access to schools – outweigh potential harms, and preferences and values and acceptability generally all favour mask-wearing.

Feasibility

Adherence is generally feasible in this age group, though there may be some issues in younger children within this range [120][138].

Justification

Although there may be a net benefit in mask wearing, this was judged to be small. After reviewing the limited evidence available on the effectiveness of mask use in this age group, a survey was completed by GDG members, among whom 80% voted in favour of a conditional recommendation for mask use. Other factors informing the conditional recommendation were low certainty of evidence, variability in preferences and values that could impact decisions and some variability in acceptability and feasibility.

Settings in which the recommendation applies were also discussed, and members voted 70% in favour of applying the recommendation to indoor settings where ventilation is known to be poor or cannot be assessed or the ventilation system is not adequate and where a distance of at least 1 metre cannot be maintained. The GDG acknowledged the importance of the guiding principles noted earlier, including the right to play and the importance of children continuing to attend school in the context of the COVID-19 pandemic.

Recommendation for adolescents 12 years of age or older

Adolescents 12 years or older should follow the same WHO recommendations for mask use as adults.

Published 7 March 2022

Practical Info

Policy and decision-makers are encouraged to ensure the following considerations are addressed when implementing the use of masks in this age group, irrespective of vaccination status.

- Even where national guidelines apply, additional considerations and adaptations for special settings such as schools, during sports or for children with disabilities or underlying medical conditions will need to be specified.
- Masks should be made accessible free of charge to children in schools, health care settings and any setting where they congregate (such as recreational areas) to ensure all children – including those living in households or geographic areas with social vulnerabilities and limited resources – have equitable access. No child should be denied access to these activities for not wearing a mask.
- Efforts should be made to accommodate children who do not have access to masks or are unable to tolerate a mask so they can participate in activities involving face-to-face gatherings. No child should be denied access to these activities for not wearing a mask.
- Routine mask breaks should be implemented when children are expected to wear masks for a longer duration.
- Age-appropriate communication should aim to help the child understand the purpose and proper use of mask-wearing.
• Key stakeholders should develop and implement strategies for ensuring each reusable mask is worn by one child and stored safely, for disposal of soiled masks (e.g. in dedicated bags or containers) and for addressing the need for masks to be changed when soiled or wet.

• The use of masks is part of a comprehensive package of preventive measures to reduce transmission, including ventilation, physical distance, hand hygiene and respiratory etiquette.

Evidence To Decision

Benefits and harms

The wearing of a well-fitted mask is associated with a decrease in SARS-CoV-2 transmission in the community and provides protective benefits to the individual [14][15][16]. A systematic review on the clinical effectiveness of masks included two RCT and three observational studies in adult populations that provided some evidence that mask-wearing in the community is associated with decreased risk of COVID-19 infection [15][16]. The systematic review found inconsistent effects of masks on reducing the risk of ILI in community settings, though a cluster RCT found that hand hygiene and face masks may prevent household transmission of influenza if applied early after symptom onset in an index case [41].

A systematic review evaluating 21 ecological studies reports that mask use is associated with reducing mortality, the incidence of disease, and hospitalization in the community [14]. Studies from the United States, Spain, Germany and the United Kingdom looked at the effectiveness of mask use in ages 4-18; twelve studies reported an association between mask use and decreased COVID-19 incidence [121][122][123][124][125][126][127][128][129][130][139][140]. However, these studies were generally observational and ecological with important shortcomings including limited reporting of other infection control measures and exposures.

The systematic review did not find evidence of serious harms with masks in adults in community settings, although bothersome harms were common. Evidence on potential harms specifically in adolescents 12-18 years of age is limited. Parents who completed an online survey conducted in France-among whom only 9% had children over the age of 11-reported behavioural and mood changes (e.g. anxiety, sadness, anguish), headaches, speaking difficulties and breathing discomfort attributed with mask-wearing [131].

The GDG previously determined that in adults, the use of masks in community settings is likely associated with a decreased risk of SARS-CoV-2 infections compared with no mask-wearing. The GDG found that evidence on the use of masks in community settings in adults is likely applicable to adolescents 12 and older due to the similarity in the incidence of SARS-CoV-2 infection (compared with young adults) and ability to adhere to mask-wearing. Emerging variants such as SARS-CoV-2 B.1.617.2 (Delta) and SARS-CoV-2 B.1.1.529 (Omicron) have been reported to have increased transmissibility [1].

The GDG judged the benefits, such as reduced transmission and facilitating increased access to schools/in-person learning, in adolescents to be small but agreed that in the context of the Delta and Omicron variants, the benefits of mask-wearing in the community setting outweigh potential harms.

Certainty of the Evidence

There is limited evidence on the benefits and harms of mask-wearing in this age group. Although ecological studies that include children aged 4-18 years have reported an association between mask mandates and a reduced incidence of infection these studies were judged to be low quality with few studies available from low and middle-income countries [121][122][123][124][125][126][127][128][129][130][139][140]. Evidence on the effectiveness of masks in adolescents can also be extrapolated from adults. Even though this evidence is indirect, it was judged by the GDG to be more applicable to this age group due to the similarity in incidence and severity of SARS-CoV-2 infection in young adults and adolescents.
**Preference and values**

There is limited data available on adolescents' perception of the value and benefits or harms of wearing masks. Some studies conducted in European settings looking at parental perceptions, showing mixed results but generally favouring mask use in children over the age of 12 [137][141][142]. Given the potential benefits of masks for preventing infections and considering the presence of bothersome but non-serious harms, the GDG determined that differences in values/preference regarding outcomes would not impact the decision to wear masks. This supports a strong recommendation, despite the low certainty of evidence.

**Resources and other considerations**

There is no formal data available on costs. Given the widespread availability and relatively low costs non-medical and medical masks, the GDG judged the impact of costs and resource availability to be low.

**Equity**

Risk factors that increase the likelihood of contracting COVID-19 include race, ethnicity, and community-level low socioeconomic status [132][133].

The GDG assessed the effects on equity as uncertain or variable as it depends on how mask use is implemented. If masks are widely available using masks could improve equity by reducing the risk of transmission overall, including among socioeconomically disadvantaged groups more impacted by COVID-19. However, there is a need to ensure that lack of access to masks does not negatively impact children (which would decrease equity) and that certain populations (such as disabled individuals) are not adversely impacted.

**Acceptability**

This recommendation was assessed by the GDG as likely acceptable in this age group. Studies on the perception of the effectiveness of mask use are limited and generally focused on European countries for children over the age of 10. The GDG considered the limited evidence and discussed knowledge of practice in their respective countries, including the evolution of acceptance of mask use as the pandemic has continued and the emergence of VOC. The GDG agreed that for children over the age of 10 mask-wearing was generally regarded as useful [137][141][142].

**Feasibility**

GDG members noted that masks are widely recommended and used in many contexts throughout the world in this age group. The feasibility of implementing this recommendation was judged to be acceptable and feasible given low concerns about tolerance and likely higher adherence to mask-wearing in older age groups [120].

**Justification**

The GDG considered the low certainty of evidence and, although the majority of the evidence was in the adult population, felt it was reasonable to extrapolate from (young) adults. The GDG noted that the benefits of mask use, such as potential reduction in transmission and ability to keep schools functioning, outweighed any potential bothersome harms and considered other factors (not preference-sensitive, low costs, acceptability, feasibility) and believed that this supported a strong recommendation.
Special populations

Good practice statement

Children with cognitive or respiratory impairments, developmental disorders, disabilities* or other specific health conditions who experience difficulties wearing a mask or have health conditions that interfere with mask-wearing should not be required to wear a mask.

* According to the Convention on the Rights of persons with disabilities, children with disabilities "include those who have long-term physical, mental, intellectual or sensory impairments which in interaction with various barriers may hinder their full and effective participation in society on an equal basis" [143].

Published 7 March 2022

Practical Info

Implementation consideration

- The individual decision for a child to wear a mask should be discussed in consultation with the child's medical provider when possible.
- A safe environment should be created for children who are not able to tolerate a mask, including requirements for caregivers, teachers or other adults interacting with the child to wear a mask when interacting with the child and to be vaccinated against COVID-19 according to national vaccination policies.
- The use of masks with a transparent component may be considered for children with hearing impairment and people who interact with them, where available. These masks should meet approved regulatory standards, if available.

Justification

The GDG acknowledged that children with several health conditions may experience difficulties or harm while wearing a mask. Despite little direct evidence but considering equity and ethical issues, the GDG determined that a good practice statement was justified.

Good practice statement

The use of a medical mask is recommended for children with a higher risk* of severe complication from COVID-19 but should be assessed in consultation with the child's medical provider.

* This includes paediatric patients with underlying non-communicable diseases (for example, diabetes, cardiac disease, chronic lung disease, chronic kidney disease, immunosuppression, obesity, mental disorders and cancer) and those living with HIV [144].

Published 7 March 2022

Justification

The GDG noted that in some low-resource settings there may be challenges for families to access medical masks or have access to a health care provider. It was proposed that in some circumstances it may be more appropriate for caregivers to wear a mask when interacting with the child. In conclusion, the GDG agreed that while there is no direct evidence, a good practice statement was justified due to this population's higher risk of COVID-19 complications.
Implementation considerations for use of masks in schools

<table>
<thead>
<tr>
<th>Implementation consideration</th>
</tr>
</thead>
</table>

Policy and decision-makers are encouraged to consider the following when implementing mask-wearing by children in school settings.

- Policies should be evidence based, agile and adjusted as needed taking into consideration factors such as changes in transmission intensity, the circulating variant of concern and the capacities for health systems to respond based on the situation.
- No child should be denied access to education because of mask-wearing or the lack of a mask due to low resources or unavailability.
- The views of teachers and educators on risks and time burden required to ensure mask adherence by children should be considered while ensuring that national policies are followed.
- Situations where wearing a mask can significantly interfere with the learning process or have a negative impact on critical school activities such as physical education, or sports and recreation (during which they may reduce ability to breathe comfortably) and meal programmes, require special consideration.
- Specific instructions and supplies should be provided for the availability, safe handling and storage of masks.
- A sufficient supply of appropriate masks should be ensured.
- Masks should not increase social inequalities in access to schools, especially for marginalized communities. No child should be denied access to these activities for not wearing a mask.
- Basic water, sanitation, hygiene, ventilation, and space requirements should be met in the school building so that IPC and public health and social measures can be implemented.
- If disposable masks are used, a system for waste management of used masks needs to be established to reduce the risk of contaminated masks being disposed of in the classroom and recreational or sports settings.

The recommendations for wearing masks in the different age groups of children in this document supersede those existing in other WHO documents published prior to this update. The following guidance documents can be used to inform policy making and programming for a comprehensive school safety strategy when re-opening or during normal operations in the context of COVID-19:

- WHO considerations for school-related public health measures in the context of COVID-19
- WB/WFP/UNESCO/UNICEF framework for school reopening

Published 7 March 2022

Justification

GDG members agreed that the recommendations on mask-wearing in this document should be implemented in the context of school settings. They also noted the importance of applying existing public health and social measures and infection prevention and control measures in schools, in addition to mask-wearing.

Home care for patients

The most up-to-date guidance for "Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance" was published 12 August 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".
Water, sanitation, hygiene, and waste management

The most up-to-date technical guidance for "Water, sanitation, hygiene, and waste management for SARS-CoV-2, the virus that causes COVID-19" was published 29 July 2020. This guidance is under review and is pending integration into "Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline".
Funding
Funding for the development of this document was provided by the United States Centers for Disease Control and Prevention (US CDC), in addition to WHO core funds. However, the views expressed in this guidance do not necessarily reflect the official policies of the US CDC.

Authorship, contributions, acknowledgements
WHO would like to thank the collaborative efforts of all those involved to make this process rapid, efficient, trustworthy and transparent.

The WHO Health Emergencies Programme COVID-19 IPC Steering group (in alphabetical order)
- Benedetta Allegranzi (Coordinator, HQ/QOC Quality of Care, IPC Hub, HQ/UHL/IHS/QOC)),
- April Baller (Medical Officer, HQ/HCR Health Care Readiness (HQ/WPE/CRS/HCR)),
- Nathan Ford, (Scientist, HQ/TAC Treatment, Care and Service Delivery UCN, (HQ/UCN/HHS/TAC)),
- Hannah Hamilton (IPC Consultant, HQ/HCR Health Care Readiness, (HQ/WPE/CRS/HCR)),
- Ying Ling Lin (Technical Officer (OSL - Medical Devices), HQ/SHO Strategic Health Operations WRE (HQ/WRE/SHO)),
- Madison Moon (Technical officer, HQ/WPE Emergency Preparedness, (HQ/WPE)),
- Alice Simniceanu (Epidemiologist, (HQ/WPE/GIH/EZD)),
- João Paulo Toledo (Technical Officer, HQ/QOC Quality of Care, IPC Hub, (HQ/UHL/IHS/QOC)),
- Maria Van Kerkhove (Unit Head, (HQ/WPE/GIH/EZD)),
- Victoria Willet (Technical officer, HQ/WPE Emergency Preparedness, (HQ/WPE)).

- Yewanda Alimi (Africa Centres for Disease Control and Prevention, Ethiopia),
- Jameela Alsalman (Ministry of Health, Bahrain, Bahrain),
- Baba Aye (Public Services International, France),
- Roger Chou (Methodologist, Department of Medicine and Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, United States of America),
- May C. Chu (Colorado School of Public Health, Center for Global Health, United States of America),
- John Conly (Cumming School of Medicine, University of Calgary, Canada),
- Barry David Cookson (Division of Infection and Immunity, University College London, United Kingdom),
- Nizam Damani (Sindh Institute of Urology and Transplant Centre, Karachi, Pakistan (Dow University of Health Sciences, Pakistan),
- United Kingdom),
- Dale Fisher (Infectious Disease Division, Department of Medicine, National University Health System, Singapore),
- Tiouiri Benaissa Hanene (Ministry of Health, Tunisia),
- Joost Hopman (Radboud University Medical Center, The Netherlands),
- Mohammad Mushhtug Husain (Institute of Epidemiology Disease Control and Research (IEDCR), Bangladesh),
- Kushlan Jayatilleke (Sri Jayewardenepura General Hospital, Nugegoda, Sri Lanka, Sri Lanka),
- Souha Kanj (American University of Beirut Medical Center, Lebanon),
- Daniele Lantagne (Tufts University, United States of America),
- Anna Levin (University of São Paulo, # Hospital das Clinicas, FM-USP, Brazil),
- Yuguo Li (Department of Mechanical Engineering, The University of Hong Kong, Hong Kong, China, China),
- Moi Lin Ling (Singapore General Hospital, SingHealth, Singapore),
- Caline Mattar (Assistant Professor of Medicine, Division of Infectious Diseases, Washington University in St Louis (WUSTL), United States of America),
- Mary-Louise McLaws (Honorary clinical Epidemiology – NSW Clinical Excellence Commission, Australia),
- Geeta Mehta (Journal of Patient Safety and Infection Control, India),
- Shaheen Mehtar (Chair Education Committee ICAN, South Africa),
- Ziad Memish (Saudi Ministry of Health, Kingdom of Saudi Arabia),
- Tochi Okwor (Nigeria Centre for Disease Control, Nigeria),
- Mauro Orsini (Ministry of Health Chile, Chile),
- Diamantis Plachouras (European Centre for Disease Prevention and Control (ECDC), Sweden),
- Mathias W Pletz (Institute for Infectious Diseases and Infection Control of the University Hospital of the Friedrich Schiller University, Germany),
- Marina Salvadori (McGill University, McGill – Department of Paediatrics, Canada),
- Ingrid Schoeman (TB Proof, South Africa),
- Mitchell Schwaber (Israel Ministry of Health, Israel),
• Wing Hong Seto (WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, China),
• Mark Sobsey (University of North Carolina and Aquagenx, LLC, United States of America),
• Paul Ananth Tambyah (National University of Singapore, Singapore),
• Anucha Apisarnthanarak Thammsat (University Hospital, Thailand),
• Andreas Voss (Professor of Infection Control, Radboud University Medical Centre, Nijmegen, NL, The Netherlands),
• Walter Zingg (Clinic for Infectious Diseases and Hospital Epidemiology, Zurich University Hospital, Zurich, Switzerland).

Methodologist
Roger Chou (Methodologist, Department of Medicine and Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, United States of America)

Declaration of conflicts of interest
R. Chou is an author on some of the evidence used to inform some recommendations. However, as a methodologist, he provided guidance to the GDG on methodologic issues and is not a voting member of the GDG. In some meetings, he presented evidence and provided clarification on methods to guide discussions regarding the EtD tables; however, all decisions were made by voting members of the GDG.

Temporary Advisor
Fernanda C. Lessa (US Centers for Disease Control and Prevention, United States of America).

Declaration of conflicts of interest
Dr F. Lessa reported she is an employee of the United States CDC who provided funding towards the development of this guideline. After consulting with the WHO Ethics Committee, it was determined Dr Lessa would contribute to discussions as she brings significant technical and field expertise to the discussions, but would be recused from voting on recommendations.

WHO reviewers
• Gertrude Avortri (Medical Officer, AF/ISD PHC Integrated Service Delivery & Primary Health Care, (AF/RGO/ARD/ISD)),
• Landry Cihambanya (Infection Prevention & Control Officer, AF/EMP Emergency Preparedness (AF/RGO/EPR/EMP)),
• Astrid Lydia Chojnacki (WP/WHE WHO Health Emergencies Programme (WHE)),
• Giorgio Cometto (Unit Head, HQ/HWP HRH Policies and Standards UHL (HQ/UHL/HWF/HWP)),
• Ivan Ivanov (Scientist, HQ/ECH Environment, Climate Change and Health, (HQ/HEP/ECH)),
• Dennis Falzon (Team lead, HQ/PCI TB Prevention, Diagnosis, Treatment, Care & Innovation, (HQ/UCN/GTB/PCI)),
• Pierre Claver Kariyo (Medical Officer, AF/ISD PHC Integrated Service Delivery & Primary Health Care (AF/RGO/ARD/ISD)),
• Catherine Kane (Technical Officer, HQ/HWP HRH Policies and Standards UHL, (HQ/UHL/HWF/HWP)),
• Babacar Ndiaye (AF/EPR Emergency Preparedness and Response, (AF/RGO/EPR)),
• Ana Paula Coutinho Rehse (Technical Officer, EU/IHM Infectious Hazard Management, EU/RGO/WHE/IHM)),
• Aparna Singh Shah (Scientist, SE/HSD Department of Health Systems Development (SE/RGO/HSD)),
• Howard Sobel (Regional Adviser, WP/MCQ Maternal Child Health and Quality Safety (DHS), (WP/RGO/DHS/PCMC)),
• Valeska Stempliuk (Advisor, Health Surveillance, Disease Prevention and Control, (AM/PAHO)),
• Maha Talat Ismail (Regional Adviser (AMR), EM/DCD Division of Communicable Disease Control (EM/RGO/DCD)),
• Bassim Zayed (Technical Specialist, EM_JOR WHO Representative's Office, Jordan, (EM/ACO/JOR)),

The WHO steering group would also like to thank the following people:
Miranda Deeves (Technical Officer, HQ/QOC Quality of Care, IPC Hub, (HQ/UHL/IHS/QOC), Luca Fontana (Technical Officer, HQ/SHO Strategic Health Operations WRE, (HQ/WRE/SHO), Paul Rogers (Programme Manager, HQ/QOC Quality of Care, (HQ/UHL/IHS/QOC)), Anthony Twywan (Consultant, HQ/QOC Quality of Care, (HQ/UHL/IHS/QOC))

The WHO Health Emergencies and UNICEF Joint Steering group for Masks for Children in the context of COVID-19 (for the update on masks for children, in alphabetical order)
• Benedetta Allegranzi, Universal Health Coverage Life Course, Integrated Health Services, Quality of Care, World Health Organization, Geneva, Switzerland
• April Baller, Health Emergencies Programme, Country Readiness and Strengthening, World Health Organization, Geneva, Switzerland
• Valentine Baltag, Maternal, Newborn, Child & Adolescent Health & Ageing, World Health Organization, Geneva, Switzerland
• Anshu Banerjee, Maternal, Newborn, Child & Adolescent Health & Ageing, World Health Organization, Geneva, Switzerland
• Anne Dejzen, UNICEF

- Yewande Alimi, Africa CDC, Ethiopia
- Jameela Alsalman, Ministry of Health, Bahrain
- Shelina Bhamani, Aga Khan University, Pakistan
- Katherine Holland, Perkins International, United States of America;
- Kushlani Jayatilleke, Sri Jayewardenapura General Hospital, Sri Lanka
- Roberta Petrucci, Médecins Sans Frontières (MSF), Geneva, Switzerland
- Mathias Pletz, Jena University Hospital/Friedrich-Schiller-University, The Netherlands
- Fiona Russell, Department of Paediatrics, The University of Melbourne, Australia
- Marina Salvadori, Public Health Agency of Canada, Canada
- Paul Anath Tambyah, National University Hospital, Singapore
- Russell M. Viner, Faculty of Population Health Sciences, University College London and Royal College of Pediatrics and Child Health, United Kingdom
- Heather Zar, School of Child and Adolescent Health at the University of Cape Town (UCT), South Africa.

Declarations of conflicts of interest

- Professor F. Russell declared receipt of funds for research to study school outbreak data and develop mitigation strategies for return to school from the Department of Health, Victoria. No actions were required.
- R. Viner declared receipt of funds for research and analysis of hospital data on COVID-19 from NHS England. No actions were required.

Methodologist

Roger Chou (Methodologist, Department of Medicine and Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, United States of America)

Declaration of conflicts of interest

R. Chou is an author on some of the evidence used to inform some recommendations. However, as a methodologist, he provided guidance to the GDG on methodologic issues and is not a voting member of the GDG. In some meetings, he presented evidence and provided clarification on methods to guide discussions regarding the EtD tables; however, all decisions were made by voting members of the GDG.

Temporary Advisor

Dr Fernanda C. Lessa (US Centers for Disease Control and Prevention, United States of America).

Declaration of conflicts of interest

Dr F. Lessa reported she is an employee of the United States CDC who provided funding towards the development of this guideline. After consulting with the WHO Ethics Committee, it was determined Dr Lessa could contribute to discussions as she brings significant technical and field expertise to the discussions but would be recused from voting on recommendations.

External reviewers (for the update on mask use by children, in alphabetical order)

- Zulfiqar A. Bhutta, Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada and Center of Excellence In Women and Child Health, The Aga Khan University Karachi, Pakistan
- Jon Klein, University of Illinois, United States of America
• Shamez Ladhani, St. George's University of London, United Kingdom
• Erin Maughan, College of Health and Human Services, George Mason University, United States of America
• Nina Schwalbe, Colombia University, United States of America

Declarations of conflicts of interest
• J. Klein reported receipt of a grant from the International Pediatric Association and UNICEF for contribution of child health and COVID-19 information to pediatric societies. No actions were required.
• E. Maughan reported she is also a member of the WHO Technical Advisory Group of Experts on Educational Institutions and COVID-19. No actions were required.

WHO and UNICEF reviewers (for the update on mask use by children, in alphabetical order)
• Ida Marie Ameda (UNICEF)
• Astrid Chojnacki (WHO-WPR)
• Landry Cihambanya (WHO-AFR)
• Delphine Sauvageot (UNICEF)
• Aparna Singh Shah (WHO-SEAR)
• Valeska Stempliuk (WHO-AMR)
• Howard Sobel (WHO-WPR),
• Maha Talaat (WHO-EMR)
• Bassim Zayed, (WHO-EMR)

The WHO would like to acknowledge the WHO Technical Advisory Group of Experts on Personal Protective Equipment (TAG PPE), who assisted with the essential Parameters of non-medical masks. (For a list of members, see here)
Annexes

This section contains two tables highlighting the application of GRADE to available literature reviewed for mask use by children.

Table 1.1. GRADE table for assessment of masks versus no mask use in community settings

<table>
<thead>
<tr>
<th>Outcome</th>
<th>SARS-CoV-2 infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number and type of studies</td>
<td>2 RCT and 3 observational studies[16][26][27][28][29][30]</td>
</tr>
<tr>
<td>Consistently</td>
<td>Moderate</td>
</tr>
<tr>
<td>Precision</td>
<td>Some imprecision*</td>
</tr>
<tr>
<td>Directness</td>
<td>Some indirectness*</td>
</tr>
<tr>
<td>Strength of evidence</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

**Main findings**
- RCT1 (cluster): Mask promotion intervention associated with increased mask use and decreased risk of symptomatic SARS-CoV-2 seroprevalence; adjusted prevalence ratio of 0.91, 95% CI 0.82 to 1.00 [29]
- RCT 2: OR 0.82, 95% CI 0.52 to 1.23 [30]
- Two observational studies reported inconsistent and imprecise estimates for mask use vs no mask use in community settings outside the home [27][28]. One observational study found mask use by all members of a household or prior to index case illness onset associated with decreased risk of secondary infection vs no mask use [26].

*Note: All studies were conducted in settings without widespread delta variant. Also, ecological studies were not included in this table but consistently found policies requiring masks were associated with decreased risk of SARS-CoV-2 infection.

*Of 2 RCTs, one reported an imprecise estimate while the other evaluated an indirect intervention (mask promotion)

Table 1.2. GRADE assessment of observational and ecological studies on Mask effectiveness

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Adult Studies</th>
<th>Ecological Studies</th>
<th>Influenza Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of studies</td>
<td>2 RCTs and 3 observational studies [26][27][28][29][30]</td>
<td>13 [121][122][123][124][125][126][127][128][129][130][137][139][140].</td>
<td>1 RCT [41] and 1 observational study [44].</td>
</tr>
<tr>
<td>Risk of bias</td>
<td>Moderate</td>
<td>High ²</td>
<td>Moderate</td>
</tr>
<tr>
<td>Consistency</td>
<td>Consistent</td>
<td>Consistent</td>
<td>Consistent</td>
</tr>
<tr>
<td>Precision</td>
<td>Some imprecision</td>
<td>Some imprecision</td>
<td>Some imprecision ⁴</td>
</tr>
<tr>
<td>Directness</td>
<td>Serious indirectness ¹</td>
<td>Serious indirectness ³</td>
<td>Serious indirectness ⁵</td>
</tr>
<tr>
<td>Strength of evidence</td>
<td>Low</td>
<td>Very low</td>
<td>Very Low</td>
</tr>
</tbody>
</table>

¹ Different population, adult evidence strength rated as moderate. Rated down 1 for children.
2 Studies did not control for the effect of concurrent interventions.

3 Different interventions. Studies did not assess actual mask-wearing or adherence to the intervention

4 RCT outcomes had wide confidence intervals (0.31 - 0.087)

5 Different outcomes were measured. Different population. RCT was a cluster household trial including adults and children. Differences in the intervention: RCT randomized households to facemasks plus 'enhanced hand hygiene' (educational materials provided).
References

Website

Website

Organization, Geneva, Switzerland 2021; Website


2006; Website


8. AFNOR Solutions. Website


10. Directorate General of Drug Administration (DGDA). Website

11. European Committee for Standardization. Website

12. GUIDELINES FOR DECLARATION OF INTERESTS (WHO EXPERTS). World Health Organization, Geneva, Switzerland Website

13. WHO handbook for guideline development, 2nd ed. World Health Organization, Geneva, Switzerland Website

COVID-19: A systematic review of ecological data. EClinicalMedicine 2021;38 101024 Pubmed Journal

15. Chou R, Dana T, Jungbauer R, Weeks C, McDonagh MS : Masks for prevention of respiratory virus infections, including SARS-CoV-2, in

16. Chou R, Dana T., Jungbauer R : Update Alert 6: Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care
and community settings. Annals of Internal Medicine 2021;174(9): Pubmed Journal


statements in guidelines suggests avoiding informal recommendations. Journal of clinical epidemiology 2021; Pubmed Journal
19. Considerations for implementing and adjusting public health and social measures in the context of COVID-19. WHO Website


23. Liu Y, Rocklöv J: The reproductive number of the delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. Journal of Travel Medicine 2021;28(7): Publisher


46. Coronavirus disease (COVID-19) advice for the public: When and how to use masks. World Health Organization, Geneva 2020; Website


75. Face Masks and GDP. Goldman Sachs Research 2020; Website


98. COVID-19 in children and the role of school settings in transmission - second update. European Centre for Disease Prevention and Control, Stockholm 2021; Website


106. National COVID-19 surveillance reports, including weekly summary of findings monitored through various COVID-19 surveillance systems. England Public Health 2020; Website


111. Elliot P, Bodineier B, Ealse O, Wang H, Haw D: Rapid increase in Omicron infections in England during December 2021: REACT-1 study. Imperial College London 2021; Website

112. James, M, Christopher J, AMy G, Kerry W, Kevin VZ, Sebastian F, et al.: Contact matrices estimated from the CoMix social contact survey, London U.K.: London School of Hygiene and tropical Medicine (Centre for mathematical modelling of infectious diseases) 2021; Website


115. Real-time assessment of community transmission findings. 2021; Website


119. Enhancing response to Omicron SARS-CoV-2 variant. World Health Organization, Geneva 2021; Website


134. Roadmap to improve and ensure good indoor ventilation in the context of COVID-19. World Health Organization, Geneva, Switzerland 2021; Website

135. Aronu AE, Chinawa JM, Nduagubam OC, Ossai EN, Chinawa AT, Igwe WC: Maternal perception of masking in children as a preventive


143. Convention on the Rights of Persons with Disabilities. Article 2